Abstract:Circulation Research, Ahead of Print. BACKGROUND:Cardiac hypertrophy is an adaptive response to pressure overload aimed at maintaining cardiac function. However, prolonged hypertrophy significantly increases the risk of maladaptive cardiac remodeling and heart failure. Recent studies have implicated long noncoding RNAs in cardiac hypertrophy and cardiomyopathy, but their significance and mechanism(s) of action are not well understood.METHODS:We measuredlincRNA-p21RNA and H3K27ac levels in the hearts of dilated cardiomyopathy patients. We assessed the functional role oflincRNA-p21in basal and surgical pressure-overload conditions using loss-of-function mice. Genome-wide transcriptome analysis revealed dysregulated genes and pathways. We labeled proteins in proximity to full-lengthlincRNA-p21using a novel BioID2-based system. We immunoprecipitatedlincRNA-p21-interacting proteins and performed cell fractionation, ChIP-seq (chromatin immunoprecipitation followed by sequencing), and co-immunoprecipitation to investigate molecular interactions and underlying mechanisms. We used GapmeR antisense oligonucleotides to evaluate the therapeutic potential oflincRNA-p21inhibition in cardiac hypertrophy and associated heart failure.RESULTS:lincRNA-p21was induced in mice and humans with cardiomyopathy. Global and cardiac-specificlincRNA-p21knockout significantly suppressed pressure overload-induced ventricular wall thickening, stress marker elevation, and deterioration of cardiac function. Genome-wide transcriptome analysis and transcriptional network analysis revealed thatlincRNA-p21actsin transto stimulate the NFAT/MEF2 pathway. Mechanistically,lincRNA-p21is bound to the scaffold protein KAP1.lincRNA-p21cardiac-specific knockout suppressed stress-induced nuclear accumulation of KAP1, and KAP1 knockdown attenuated cardiac hypertrophy and NFAT activation. KAP1 positively regulates pathological hypertrophy by physically interacting with NFATC4 to promote the overactive status of NFAT/MEF2 signaling. GapmeR antisense oligonucleotide depletion oflincRNA-p21similarly inhibited cardiac hypertrophy and adverse remodeling, highlighting the therapeutic potential of inhibitinglincRNA-p21.CONCLUSIONS:These findings advance our understanding of the functional significance of stress-induced long noncoding RNA in cardiac hypertrophy and demonstrate the potential oflincRNA-p21as a novel therapeutic target for cardiac hypertrophy and subsequent heart failure.

The piRNA CHAPIR regulates cardiac hypertrophy by controlling METTL3-dependent N6-methyladenosine methylation of Parp10 mRNA

The Pirna CHAPIR Regulates Cardiac Hypertrophy by Controlling METTL3-dependent N 6 -Methyladenosine Methylation of Parp10 Mrna

Long non‐coding RNA cardiac hypertrophy‐associated regulator governs cardiac hypertrophy via regulating miR‐20b and the downstream PTEN/AKT pathway

The Long Noncoding RNA Chaer Defines an Epigenetic Checkpoint in Cardiac Hypertrophy

Targeting a Cardiac Abundant and Fibroblasts-Specific Pirna (cfrpi) to Attenuate and Reverse Cardiac Fibrosis in Pressure-Overloaded Heart Failure.

PARP1 interacts with HMGB1 and promotes its nuclear export in pathological myocardial hypertrophy

MiR-495-3p promotes cardiac hypertrophy by targeting Pum2

PARP1 Interacts with STAT3 and Retains Active Phosphorylated-Stat3 in Nucleus During Pathological Myocardial Hypertrophy.

3′ untranslated region of Ckip-1 inhibits cardiac hypertrophy independently of its cognate protein

PIWI‐Interacting RNA HAAPIR Regulates Cardiomyocyte Death After Myocardial Infarction by Promoting NAT10‐Mediated ac 4 C Acetylation of Tfec mRNA

MicroRNA-19a/b-3p protect the heart from hypertension-induced pathological cardiac hypertrophy through PDE5A.

The Cross-Talk Between PARylation and SUMOylation in C/EBPβ at K134 Site Participates in Pathological Cardiac Hypertrophy

Histone H4R3 symmetric di-methylation by Prmt5 protects against cardiac hypertrophy via regulation of Filip1L/β-catenin.

Therapeutic Inhibition of LincRNA-p21 Protects Against Cardiac Hypertrophy

piR112710 attenuates diabetic cardiomyopathy through inhibiting Txnip/NLRP3-mediated pyroptosis in db/db mice

The lncRNA MIAT regulates CPT-1a mediated cardiac hypertrophy through m6A RNA methylation reading protein Ythdf2

METTL3-mediated m6A modification of OTUD1 aggravates press overload induced myocardial hypertrophy by deubiquitinating PGAM5

PARP-1 Inhibition Attenuates Cardiac Fibrosis Induced by Myocardial Infarction Through Regulating Autophagy.

Circular RNA circRNA_000203 aggravates cardiac hypertrophy via suppressing miR-26b-5p and miR-140-3p binding to Gata4

SIRT3 inhibits cardiac hypertrophy by regulating PARP-1 activity

PARP-2 knockdown protects cardiomyocytes from hypertrophy via activation of SIRT1.